0001474835-18-000002.txt : 20180321 0001474835-18-000002.hdr.sgml : 20180321 20180320232142 ACCESSION NUMBER: 0001474835-18-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180321 DATE AS OF CHANGE: 20180320 EFFECTIVENESS DATE: 20180321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intellipharmaceutics International Inc. CENTRAL INDEX KEY: 0001474835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-308176 FILM NUMBER: 18703231 BUSINESS ADDRESS: STREET 1: 30 WORCESTER ROAD CITY: TORONTO STATE: A6 ZIP: M9W 5X2 BUSINESS PHONE: 416-798-3001 MAIL ADDRESS: STREET 1: 30 WORCESTER ROAD CITY: TORONTO STATE: A6 ZIP: M9W 5X2 FORMER COMPANY: FORMER CONFORMED NAME: IntelliPharmaCeutics International Inc. DATE OF NAME CHANGE: 20091020 D 1 primary_doc.xml X0708 D LIVE 0001474835 Intellipharmaceutics International Inc. 30 WORCESTER ROAD TORONTO A6 ONTARIO, CANADA M9W 5X2 416-798-3001 ONTARIO, CANADA IntelliPharmaCeutics International Inc. Corporation true Isa Odidi 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Director Amina Odidi 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Director Eldon Smith 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Kenneth Keirstead 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Bahadur Madhani 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Director Andrew Patient 30 Worcester Road Toronto A6 ONTARIO, CANADA M9W 5X2 Executive Officer Pharmaceuticals $1,000,001 - $5,000,000 06b false 2018-03-13 false true true false 0 H.C. Wainwright Co., LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 NY NEW YORK TX TEXAS false 1968750 1968750 0 Represents the aggregate warrant exercise price for the warrants covered by this Form D, which were issued in a private placement ("PP") conducted concurrently with a registered direct offering ("RDO") of common shares not the subject of this Form D. false 5 245000 0 H.C. Wainwright Co., LLC ("Wainwright") received the above sales commissions, and $65,000 in expense reimbursements in connection with the RDO and the PP of the warrants. Wainwright also received warrants to purchase an aggregate of 291,667 common shares. 0 false Intellipharmaceutics International Inc. Andrew Patient Andrew Patient Chief Financial Officer 2018-03-20